// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1321 Abstracts

Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma.

Collin M. Blakely - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

An ultra-deep next generation sequencing method for cfDNA detection in NSCLC patients.

Yu Yao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Utility of liquid biopsies to assess circulating tumor DNA in patients with lung adenocarcinoma.

Maria Clemence Schwaederle - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Retrospective analysis of circulating tumor DNA of archived plasma samples.

Wei Shen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Heparin

TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials.

Matthew Krebs - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.

Sarina Anne Piha-Paul - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Acetazolamide Sodium

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.

Kei Muro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Adrucil injection

TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)Liquid biopsy for biomarkers discovery.

Elena Verzoni - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Pazopanib

Treat ER+ight: Treatment of Canadian postmenopausal women with ER+ HER2- advanced breast cancer in the real-world setting with hormone therapy targeted therapy.

Nadia Califaretti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.

Katherine Clifton - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.

Daniele Rossini - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bevacizumab

Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.

Nicholas C. Turner - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fulvestrant

The integrated genomic and immune landscapes of lethal metastatic breast cancer (MBC).

Leticia De Mattos-Arruda - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.

Reinhard Dummer - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dabrafenib Mesylate

Longitudinal ctDNA analysis to enable early assessment of prognosis in lung adenocarcinoma in the absence of matched tissue biopsy.

Xiaoju Max Ma - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.

Begona Jimenez Rodriguez - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of rapidly progressing stage IV disease (Stage IVprog).

Lorenzo Gerratana - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Circulating tumor DNA as biomarker in mutant malignant melanoma.

Jan Braune - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).

Ben C. Creelan - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.

Stephanie Yaung - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved